Literature DB >> 30468409

Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer.

Şükrü Tüzmen1,2, Galen Hostetter2,3, Aprill Watanabe2,4, Cumhur Ekmekçi2,5, Patricia E Carrigan6,7, Ishaiahu Shechter8, Olli Kallioniemi9, Laurence J Miller6, Spyro Mousses2,10.   

Abstract

AIM: To help characterize the FDFT1 gene and protein expression in cancerCholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.

Entities:  

Keywords:  ; TMA; cancer; cholesterol; gene expression; immunohistochemistry; lipidrafts; microdomains; plasma membrane; qPCR

Mesh:

Substances:

Year:  2018        PMID: 30468409     DOI: 10.2217/pme-2016-0058

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  6 in total

1.  Putative Genes and Pathways Involved in the Acne Treatment of Isotretinoin via Microarray Data Analyses.

Authors:  Biao Chen; Peishan Li; Jun Li; Jinping Chen
Journal:  Biomed Res Int       Date:  2020-06-29       Impact factor: 3.411

Review 2.  Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments.

Authors:  Nguyen Thi Ha; Chang Hoon Lee
Journal:  Cells       Date:  2020-10-25       Impact factor: 6.600

Review 3.  Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.

Authors:  Michela Codini; Mercedes Garcia-Gil; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

4.  Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.

Authors:  Robert J Rabelo-Fernández; Ginette S Santiago-Sánchez; Rohit K Sharma; Abiel Roche-Lima; Kelvin Carrasquillo Carrion; Ricardo A Noriega Rivera; Blanca I Quiñones-Díaz; Swetha Rajasekaran; Jalal Siddiqui; Wayne Miles; Yasmarie Santana Rivera; Fatima Valiyeva; Pablo E Vivas-Mejia
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 6.208

Review 5.  Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review.

Authors:  M Kanmalar; Siti Fairus Abdul Sani; Nur Izzahtul Nabilla B Kamri; Nur Akmarina B M Said; Amirah Hajirah B A Jamil; S Kuppusamy; K S Mun; D A Bradley
Journal:  Cell Mol Biol Lett       Date:  2022-01-29       Impact factor: 5.787

6.  Squalene synthase predicts poor prognosis in stage I-III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression.

Authors:  Huihong Jiang; Erjiang Tang; Ying Chen; Hailong Liu; Yun Zhao; Moubin Lin; Luwei He
Journal:  Cancer Sci       Date:  2022-01-06       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.